Maitri Kalra, MBBS

Maitri Kalra practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Maitri Kalra's NPI, 1457615270, was assigned on June 26, 2012. Maitri Kalra holds Maryland license D0093625.

Maitri Kalra's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Maitri Kalra's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Maitri Kalra is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Maitri Kalra to 1 more hospital and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Maitri Kalra practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Maitri Kalra's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Maitri Kalra's licenses on file in 2 states: Maryland and Indiana.

CMS data shows 726 Medicare services from Maitri Kalra across 8 procedure codes in 2024, for 321 Medicare patients. Medicare paid $68,371 for them.

CMS counts 321 Medicare patients who saw Maitri Kalra in 2024. The largest group is 65 to 74, with 155 patients. 75% of them have cancer, and 75% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Maitri Kalra's median patient age at 68, with 97% women.

In 2024, Maitri Kalra wrote 625 Medicare Part D claims for 179 patients. 87% of them were for generic drugs. CMS names the drug for 526 of them, across 12 drugs with 11 or more claims each, at $804,751 in total drug cost. In 2023, CMS named 346 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Maitri Kalra for performance year 2024, reported as part of a group. CMS lists Maitri Kalra as offering telehealth.

Dmand AI links 10 papers to Maitri Kalra, published from 2018 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols and Carboplatin. Maitri Kalra's most frequent co-authors are Rafat Abonour, MD, Nabil Adra, MD and Krittapoom Akrawinthawong, MD.

Dmand AI links Maitri Kalra to 4 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Small Cell Lung Carcinoma and Breast Diseases. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 37 general payments to Maitri Kalra from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 47% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,997.